Genscript Biotech Co., Ltd. has made an announcement. Its associate company Legend Biotech Corporation, which is listed on the NASDAQ Global Select Market in the form of American Depositary Shares, submitted a Form 6-K to the U.S. Securities and Exchange Commission on June 1, 2026, and issued a press release.
The release disclosed initial human trial data for its investigational DLL3-targeted CAR-T cell therapy, LB2102, in patients with relapsed or refractory small cell lung cancer or large cell neuroendocrine carcinoma.
It also presented the latest analyses from the CARTITUDE program.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments